Life at the top
The breathtaking views at Courchevel keep millionaires, royalty and Beyoncé coming back, writes Susan Mitchell.
To find exact match, try putting a word or phrase inside quotes. For example, "tallest building".
The breathtaking views at Courchevel keep millionaires, royalty and Beyoncé coming back, writes Susan Mitchell.
A former policy adviser appointed by minister James Reilly has stopped working for the health service.
Ireland's payouts completely off the scale compared to other countries'
Patients have developed liver cancer and others have seen their condition deteriorate enough to force them onto a liver transplant list.
In August, The Sunday Business Post highlighted the practice of women returning from Britain to Ireland mid-abortion. Below is an edited version of Susan Mitchell's report of August 24.
The number of top earners in the education sector has soared by almost 300 per cent since 2010, a major survey by this newspaper reveals.
Hospital consultants are continuing to breach the terms of their public contract at St Vincent's Hospital.
Nineteen legal cases have been taken against a single eye laser clinic since 2009, prompting serious concern about the hard-sell techniques being used.
The government will introduce new legislation that will facilitate staggered payments in medical negligence cases this year.
The interaction of the young pregnant woman with agencies and individuals remain at the heart of the latest abortion controversy.
More patients are being treated with electroconvulsive therapy without their consent, new figures show.
Patients infected with hepatitis C and their doctors are appealing to health minister Leo Varadkar to facilitate a rapid access programme to a new new life-saving drug, Sovaldi.
Hundreds more hospital consultants with public contracts are facing a major rise in the cost of their clinical indemnity.
Doctors say the impulse-driven' decision following the election hammering earlier this year will be fraught with difficulty and inequality, writes Susan Mitchell.
A drug that can extend the lives of women with advanced breast cancer by six months has been rejected for use in the public health system.